CORTICOSTEROIDE
Metilprednisolona
Ficha de consulta para farmacia hospitalaria: indicaciones, preparación, dilución, estabilidad y compatibilidad de metilprednisolona, con la fuente oficial de cada dato.
- Proteger de la luz
También conocido como: methylprednisolone, Metilprednisolona (succinato sódico), Solu-Medrol
Presentación
Succinato sódico de metilprednisolona, polvo — documentado: Eugia (FDA)
| Producto de referencia | Titular | Vía | Fuente |
|---|---|---|---|
| Methylprednisolone Sodium Succinate | Eugia US LLC | Intramuscular, Intravenous | FDA (DailyMed) |
¿Para qué sirve metilprednisolona? Indicaciones autorizadas
INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of…
FDA (DailyMed) · Methylprednisolone Sodium Succinate · Indications and usage · texto original en inglésLeer la sección completa
INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
Contraindicaciones de metilprednisolona
CONTRAINDICATIONS Methylprednisolone sodium succinate for injection is contraindicated: in systemic fungal infections and patients with known hypersensitivity to the product and its constituents. The methylprednisolone sodium succinate for injection 40 mg presentation includes lactose monohydrate produced from cow’s milk. This presentation is therefore contraindicated in patients with a known or suspected…
FDA (DailyMed) · Methylprednisolone Sodium Succinate · Contraindications · texto original en inglésLeer la sección completa
CONTRAINDICATIONS Methylprednisolone sodium succinate for injection is contraindicated: in systemic fungal infections and patients with known hypersensitivity to the product and its constituents. The methylprednisolone sodium succinate for injection 40 mg presentation includes lactose monohydrate produced from cow’s milk. This presentation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products because it may contain trace amounts of milk ingredients. for intrathecal administration. Reports of severe medical events have been associated with this route of administration. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Additional contraindication for the use of methylprednisolone sodium succinate for injection preserved with benzyl alcohol: Formulations preserved with benzyl alcohol are contraindicated for use in premature infants (see WARNINGS and PRECAUTIONS, Pediatric Use ).
Reconstitución de metilprednisolona
Solo agua inyectable o agua bacteriostática con alcohol bencílico (algunas presentaciones contienen alcohol bencílico).
Dilución de metilprednisolona
No mezclar con otras soluciones (incompatibilidades físicas). Si se diluye, añadir el diluyente adecuado al vial.
Administración de metilprednisolona
IV lenta, infusión o IM.
Estabilidad y periodo de validez
| Condición | Tiempo | Nota |
|---|---|---|
| Reconstituida (sin diluir), 20–25 °C | 2 días | |
| Diluida, <25 °C | 4 h | |
| Diluida, 2–8 °C | 24 h |
Compatibilidad de metilprednisolona
Compatible con
- Agua inyectable
Incompatible con
- No diluir ni mezclar con otras soluciones (posibles incompatibilidades físicas)
Conservación y protección de la luz
Polvo a 20–25 °C.
Proteger de la luz.
Advertencias
- Los bolos rápidos de dosis altas se han asociado a arritmias y colapso cardiovascular.
Diferencias entre fuentes oficiales
- La búsqueda en AEMPS devolvió comprimidos de Urbason (otra forma farmacéutica), que no se usaron.
Fuentes
- FDA (DailyMed) · Methylprednisolone Sodium SuccinateEugia US LLC · Succinato sódico, viales 40 mg, 125 mg, 500 mg y 2 g (polvo liofilizado) · versión 2026-06-12
Interacciones de metilprednisolona
9 medicamentos del catálogo con una interacción documentada en sus fichas oficiales. Abre cada una para ver el efecto, la recomendación y su fuente.
- AcenocumarolMayor
- Anfotericina BMayor
- AprepitantMayor
- CiclosporinaModerada
- ClaritromicinaModerada
- EritromicinaModerada
- FenitoínaModerada
- NeostigminaModerada
- TacrolimusModerada
Diagnósticos relacionados
Diagnósticos que la ficha técnica de metilprednisolona menciona en sus indicaciones. Cada uno abre su definición y los demás medicamentos indicados.
Identificación
- SNOMED CT (VTM)
- 27242001
- RxNorm
- 6902
Información de consulta profesional extraída de las fichas técnicas y etiquetas oficiales citadas. Las condiciones de preparación, estabilidad y administración dependen del producto concreto: verifica el documento del producto que utilizas. No sustituye el criterio clínico ni la valoración del paciente.